Introduction
Whether the optimal molecular target has been selected in a given pathway is often an open question in early drug discovery. However, despite the ubiquitous nature of this question, very few useful rules have been unequivocally identified (cf. Agoram and Demin, 2011; Benson et al., 2012; Stock et al., 2015) . Techniques such as sensitivity analysis of mathematical models of systems can be employed (cf. Lebedeva et al., 2012) , however these assume accuracy of structure and parameterisation of complex differential models and have yet to become mainstream in drug discovery. Thus, target identification is driven by an intuitive feel for what is right, coupled with empirical demonstration of pharmacological efficacy in pre-clinical drug development. An example of such a gut feel is that targeting the top of a pathway is the optimum point of intervention in the context of efficacy because this is the initiating step.
However, signal transduction is very complex, with parameters for drug pharmacology and pharmacokinetics, ligand and receptor concentration, rate of signal transduction and feedback processes potentially interacting to confound any attempt to intuitively grasp the best way of controlling the system, as recently outlined by Danhof (2016) . In this paper we explore this using a simplified model of receptor tyrosine kinase (RTK) signalling. The model incorporates appropriate physiological considerations and molecular signal transduction events up to and including the phosphorylation of RTK.
The use of a simplified model has the advantages that its structure becomes transparent, is easily communicated, the assumptions can be clearly and succinctly specified and mathematically, the relation between the contributing processes can be identified analytically tested and easily tested through simulations. Thus, the likely gamut of parameter space can be explored and conclusions drawn that can be ascribed to some fundamental property of the system. In addition, by integrating physiological information the model enables interrogation of common drug discovery questions, regarding for instance dosing, route of administration and drug inter-compartmental clearance.
Receptor tyrosine kinases (RTKs) are ubiquitous high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones; there are 58 encoded in the human genome (cf. Haugh and Lauffenburger, 1998; Robinson and Wu, 2000) . They are located across the cell membrane with a binding domain BDR facing extra-cellular space and a kinase domain RKD facing intra-cellular space, as shown in Fig. 1 . They have been shown not only to be key regulators of normal cellular processes, but also to have a critical role in the development and progression of many types of diseases such as pain and neurological disorders (cf. Zweifel et al., 2005) .
RTKs are usually embedded in complex biological networks, where they can be viewed as critical transduction modules (cf. Hartwell et al., 1999; Shankaran et al., 2007) . Thus, detailed knowledge of the http://dx.doi.org/10.1016/j.ejps.2017.05.049 Received 20 May 2017; Accepted 22 May 2017 dynamics and workings of RTKs is important for understanding the dynamics of larger networks. In addition, from a mathematical point of view, they have a beautiful internal structure.
Since RTKs interact with the interstitial fluid (IF) and the interior of the cell, the model involves two compartments: the IF compartment and the interior of the cells of the cell population, referred to as the cellular compartment. Throughout this paper, compounds and quantities pertaining to the IF compartment are referred to by a subscript "1" and those pertaining to the cellular compartment by a subscript "2".
The receptor is activated by an endogenous ligand L 1 in the interstitial fluid compartment which binds the receptor R 1 and forms a complex RL 1 and thereby effects a conformational change of the receptor, changing K 2 into KL 2 in the cellular compartment. Subsequently, KL 2 is then phosphorylated to form P 2 and so unleash a cellular response. The geometry of the two-compartment model and the complex of reacting compounds are shown schematically in Fig. 1 .
In this figure we also show how the large molecule inhibitor, denoted by D A , is supplied to the interstitial fluid compartment and binds the ligand to form a complex D A L 1 and so prevents L 1 from binding the receptor, and in the end the phosphorylisation of KL 2 into P 2 . Small molecule inhibitors, denoted by D B , are also supplied to the interstitial fluid compartment (D B,1 ). However they can freely pass the cell membrane and enter the cellular compartment (D B,2 ). There, they bind the kinase domains of the receptor and the ligand-receptor complex, so inhibiting phosphorylisation into P 2 .
Several cellular, one-compartment models of RTK signalling have been published (e.g. Sasagawa et al., 2005) . However, when we applied such systems biology models to explore the effect of a drug blocking the ligand we found that the model predicted that very high doses were required to produce a significant pharmacological effect. The aim of the present study is therefore to investigate the impact of inhibitors according to a recently proposed physiologically more realistic model in which the interstitial fluid and the cell are treated as separate compartments.
In some instances, models for ligand-receptor interactions in the context of Target-Mediated Drug Disposition (TMDD) exhibit kinship with the RTK model studied in this paper. For such TMDD models we refer to cf. Gibiansky et al. (2008) , Mager and Jusko (2001) , Mager and Krzyzanski (2005) , Peletier and Gabrielsson (2012) and Dua et al. (2015) .
In this paper we make a quantitative comparison between (i) the impact of large-and small-molecule drugs according to this new model and (ii) the impact of small molecule drugs according to a two-and a one-compartment model.
Methods
The impact of drugs on signal transmission through RTKs is estimated using a recently developed system pharmacological model which is small enough to be transparent and complex enough to allow for different dosing methods and drug properties (cf Benson et al., , 2016 . This model is used to simulate different provocations.
The basic RTK-model
The RTK-system shown in Fig. 1 is modelled by a system of reactions, some located in the interstitial fluid (IF) compartment with volume V if and some in the cellular compartment with volume V c . The reactions in the IF compartment and the cellular compartment are assumed to follow mass-action kinetics based on concentrations. Signalling across the cell membrane takes place through molecules, and hence, rather than by concentrations, their dynamics is determined by amounts of molecules.
The model is composed of three parts: (i) the IF compartment, (ii) the cellular compartment and (iii) the signalling across the cell membrane.
In the IF compartment
Ligand is supplied from an endogenous source, binds the binding domain of the receptor and is degraded according to a first order process:
where L 1 , R 1 and RL 1 are the concentrations of ligand, receptor and complex (in μM).
In the cellular compartment
The kinase domain of the receptor is in equilibrium with the receptor pool PK 2 and the kinase domain of the ligand-receptor complex is phosphorylated by a first order process into P 2 :
where K 2 , KL 2 and P 2 are the concentrations of receptor, complex and product (in μM).
Across the cell membrane
The signalling between R 1 and RL 1 in the binding domain of the receptor, and K 2 and KL 2 in the kinase domain takes place through the molecules and is therefore modelled by the relations
in which R* 1 , RL * 1 , K * 2 , and KL * 2 denote the number of molecules of these compounds and Cl R21 , Cl R12 , Cl K21 and Cl K12 are the equilibrium constants (1/min). To translate numbers of molecules into concentrations R 1 , RL 1 , K 2 and KL 2 measured in μM, involves dividing by 10 −6 , by the number of Avogadro N a , and the respective volumes V if or V c : For simplicity we assume throughout that , that the cross-membrane signalling is very fast. Specifically, with the equilibrium constant Cl given in Table B1 , the concentrations in the IF compartment and in the cell compartment approach quasi-equilibrium with a half-life that amounts to t 1/2 = 2 × 10 −4 min. This means that by Eq. (2.4) we may effectively assume that N. Benson et al. European Journal of Pharmaceutical Sciences 109 (2017) S140-S148
It is established in
Evidently, V c ≪ V if so that μ is a very small quantity. In this paper we take V if = 12 L and V c = 10 −3 L, so that μ = 0.833 × 10 −4 (cf.
Appendix B).
In light of these two identities the full model can be reduced to one involving only three quantities, L 1 , R 1 and RL 1 : The phosphorylation of RL 1 into the product P 2 can then be computed by means of the equation
The origin of the factor 1/2 in the second and third equations is the following: by adding the equations for RL 1 and μKL 2 , the fast crossmembrane terms drop out. On the left hand side we then obtain d/dt (RL 1 + μKL 2 ) = 2d/dt(RL 1 ). Dividing by 2 results in the factor 1/2. Similarly, adding the equations for R 1 and μK 2 , results in a factor 1/2 in te equation for d/dt(R 1 ). The details of this derivation can be found in .
An elementary computation shows that when k cat = 0 the steady state concentrations are given by Summarising, ligand L 1 is supplied endogenously into the IF compartment, where it binds the receptors on the cell membrane at their binding domain (BDR). Their kinase domain (RKD) is activated and through phosphorylation generates a product P 2 , whilst receptors inside the cell are kept at a level by staying in equilibrium with a pool of receptors (PK 2 ). Thus, when the system (2.6) has reached a steady state, phosphorylation proceeds at a constant rate and P 2 increases monotonically at a constant slope. This process is illustrated in Fig. 2 , where the systems starts from initial concentrations L 0 , R 0 and RL 0 for which the system (2.6) is stationary in the absence of phosporylation (k cat = 0). Fig. 2 shows two time scales: a brief one in which RL 1 and μP 2 quickly reach a quasi-equilibrium and a long one in which L 1 and μP 2 change gradually. Remark 1. It is interesting to note that the system (2.6) is very similar to the basic model for Target-Mediated Drug Disposition (cf. Mager and Jusko, 2001 ). In fact, were it not for the factor 1/2, the systems would be identical.
Inhibition
We compare two modes of inhibition, one involving large-molecule drugs, such as monoclonal antibodies (mAb) which bind the ligand and thus prevent it from binding the receptors and make the ligand-receptor complex needed for phosphorylation. The other mode involves smallmolecules which bind the receptors and thus compete with co-substrate ATP for binding places on the receptors.
Large-molecule drugs, denoted by D A,1 because they are confined to the interstitial fluid, bind the ligand (L 1 ) with a second order rate constant k Df to form a complex D A L 1 , which in turn dissociates with a first order rate constant k Db . Both D A,1 and D A L 1 degenerate through first order processes with rate constants, k degD and k degDL respectively. Thus,
The cross-membrane signalling proves to be so quick (cf. ) that we are justified to describe the dynamics by the reduced model (2.6), together with equations for the drug D A,1 and its ligand-complex D A L 1 :
As in the RTK-model, the phosphorylation is described by Eq. (2.7).
Small-molecule drugs
Such drugs are assumed to move freely from the interstitial fluid into the cell and back, but the drug-action takes place in the cellular compartment. There the drug (D B,2 ) binds the receptor (K 2 ) and the receptorligand complex (KL 2 ), and the resulting complexes break down into (free drug) (D B,2 ) and degraded receptors. The reaction equations are Table B1 and initial data from Table B2 . On the left is the long time behaviour and on the right is the short time behaviour.
In the interstitial fluid compartment, the drug concentration (D A,1 ) is only governed by exchange with the cellular compartment through passive diffusion and elimination by a first order process with the rate k degD :
Here PS is the permeability surface coefficient of the cell membrane.
In the cellular compartment, the drug concentration (D B,2 ) is determined by drug-exchange between compartments, as well as by reactions and eliminations summarised by the reaction equations in Eq. (2.12):
(2.14)
When we multiply Eq. (2.14) for the cellular compartment by μ = V 2 /V 1 and add the result to Eq. (2.13) for the interstitial compartment we obtain
where we have used the fact that μ ≪ 1, and that D B,1 = D B,2 because of the rapid exchange between the compartments. It has been shown in Benson et al. (2016) that including the drug reactions involving the kinase domain of the receptors and their ligand complexes results in the following extension of the reduced ligand-receptor system (2.6): As in the pervious models, the phosphorylation of RL 1 is given by
In summary, the system of Eqs. (2.6) and (2.7) comprises the -reduced -model for the RTK system. Large and small molecules each have their own extension of the RTK system: Eq. (2.11) for large molecule inhibitors and Eq. (2.16) for small molecule inhibitors.
Simulations
Whereas the models describing inhibition of the generation of the cellular product P 2 are complex and involve a range of individual processes it is sometimes possible to distinguish different time scales associated with these processes. In order to gain insight into the time scales involved, we carry out simulations for small-molecule drug inhibitors taking for realistic parameter values and concentrations.
In Fig. 3 we show how in Scenario 2 the small-molecule drug inhibits the cellular response, when it is supplied to the IF compartment (D B,1 (0) = 1 μM), initially there is no drug in the cell compartment (D B,2 (0) = 0 μM) and the amount of drug is preserved (cf. Table 3 .2).
The parameter values of the RTK systems (2.6) and (2.7) are listed in Appendix B.
In the left panel we see how the drug binds to the receptor and the receptor-ligand complex, in the middle panel we see how the concentration of receptor-ligand complex decreases, whilst that of the drug-receptor complex increases, and in the right panel the drug-receptor complex continues to rise for a long time until it eventually settles on a relatively large value.
Plainly, in the dynamics of drug binding and elimination shown in Fig. 3 it is possible to distinguish three temporal phases: These different temporal phases make it possible to reduce the full model to smaller, more tractable models in which some of the compounds are "active" whilst the others are in a quasi-steady state following the "active" compounds. This, in turn makes it possible to derive quantitative estimates.
We study five scenarios which focus on the impact of (i) Model structure: a two-compartment model which the underlying physiology and a one-compartment model which is restricted to the cell. Table B1 and on-and off rates for the inhibitor in Table 3 .1.
(ii) Drug type: large-versus small molecule drug, each with its own mechanism of action, affinities, elimination rates.
In the first three scenarios we compare the effectiveness of a large molecule inhibitor, which cannot enter the cell (Scenario 1), and a small molecule inhibitor which either can easily pass the cell membrane (Scenario 2), or is confined to the cell (Scenario 3). Thus, in the first two scenarios the model comprises two compartments, and in the third scenario a one-compartment model is employed.
For the sake of transparency we assume that in these three scenarios (i) the drug doses are the same, (ii) the mode of administration (initial iv bolus) is the same, (iii) the binding rates are the same and (iv) there is no drug clearance.
In two further scenarios we adopt a two-compartment structure and focus on comparing large-molecule drugs, such as monoclonal antibodies (Scenario 4), and small-molecule drugs (Scenario 5) with realistic dosing regimes, dose values, as well as binding and clearance properties.
It should be observed that in the event of an iv bolus dose the inhibitory effect of either drug is transient, since there is a constant endogenous supply of ligand and inside the cell there is constant pool of receptor. Thus, a key question will be for how long the inhibitory effect will last in the different scenarios. For periodic dosing, as in Scenario 5, the inhibitory effect brings down the production of P 2 in a permanent way.
Results
Large-and small-molecule drugs have been compared in one-and two-compartment models in two types of scenarios. The first three scenarios were focussed on deciding which kind of model can best be used. The last two scenarios are focussed on the question, as to what kind of drug should be used.
One-or two-compartment model?
We compare the impact of a large-and a small molecule drug through three scenarios. In the first two scenarios the drug is supplied to the IF compartment and in the third scenario, a small molecule drug is supplied to the cellular compartment and it is assumed that it cannot pass through the cell membrane. The characteristics of the three scenarios are listed in Table 3 .1.
For the sake of transparency, the drug doses in the three scenarios are the same, as are the on-and off-rates of the drug, whether it binds to the ligand or to the receptor and its ligand-complex. In all three scenarios we assume that drug, free and bound, does not degenerate. The rates are given in Table 3 .2.
In Fig. 4 we compare the generation of product P 2 in the cellular compartment. Plainly, inhibition through the first two scenarios when drug is supplied to the IF compartment, is much more effective than through the third when drug is supplied to the cell compartment.
It has been demonstrated in Benson et al. (2016) that the reason lies in the fact that the amount of drug supplied is much greater in the first two compartments than in the third. Consequently, in the third scenario it takes less time to replenish the amount of receptor lost to binding the drug and resume the original rate of producing the product P 2 .
A mathematical analysis of the two-compartment models yields the following precise analytical estimates for the initial growth of P 2 , as well as its large time asymptote: In this estimate the constants A L and A S only depend on the ligandreceptor system. In the estimates for λ given above, the numerical values result from the data of the RTK-system listed in Appendix B.
Large-or small-molecule drug?
Whereas in Section 3 the impact of large and small molecule drugs were compared under largely the same conditions: same drug-target affinity, same dosing regimen and no direct elimination, we now compare the impact under circumstances tailored to the nature of the drug. Thus for each type of inhibitor, we make realistic -and differentassumptions about (i) binding constants, (ii) drug elimination rates, (iii) degeneration of drug complexes and (iv) dosing regimes. We collect them into two scenarios: Scenario 4 for the large molecule drugs and Scenario 5 for the small molecule drugs.
The following characteristic properties of the drugs have been used in selecting parameter values:
• Large molecule drugs usually have higher affinity to their target than small molecule drugs. Their on-rate is usually smaller.
• Large molecule drug are generally eliminated from the IF compartment fairly slowly with a half-life of about 21 days (t 1/ 2 = 21 days or 30,240 min).
• Small molecule drugs are generally eliminated rapidly from the IF compartment the half-life being about 4 h, i.e., 240 min. The degeneration rate of the complex, k degDR , has been chosen 1/10 × k PKb .
• Because of the differences in elimination rate, large molecule drugs are usually given less frequently than small molecule drugs.
The specific parameter values used in the simulations are listed in Table 3 .3.
For both kinds of molecules, drug is supplied through periodic (iv) bolus administrations resulting equivalent to a drug dose D 0 (in μM). For each of the two drug types, D 0 is given in Table 3 .4, together with the time between administrations. The doses have been so chosen that D 0 /K d is the same for both types of drug.
The simulations for the large-and the small molecule scenarios, respectively, Scenario 4 and Scenario 5, are shown in Fig. 5 .
We make the following observations:
• In both scenarios growth of the product P 2 is comparable for the choice of parameters made in Tables 3.3 and 3 .4.
• The amount of small-molecule drug supplied over 21 days is very different from that of the large molecule drug. Not only are the bolus doses of the small molecule drug larger by a factor of 10, the frequency of dosing is larger by a factor of about 20. The total amount that is supplied is therefore about a factor 200 larger for the small molecule.
On the other hand the small molecule inhibitor is eliminated a great 
deal faster than the large molecule drug. Since t 1/2 ≈ 9 h, at the end of one day much drug has been eliminated. It is evident that the comparison of the two scenarios will be sensitive to the value of the drug parameters such as the binding rates and the elimination rates. The theory developed in Section 3 makes it possible to obtain quantitative estimates for this dependence.
Obviously, the rate k degD with which drug is eliminated from the system is a critical quantity. For instance, when drug is supplied periodically, say with period T, then whether the half-life t 1/2 is large or small with respect to T makes a difference. We demonstrate through three simulations how the growth of P 2 in Scenario 5 is affected by this elimination rate k degD . This is done in Fig. 6 for three values which decrease by a factor of 2/3. Evidently, the impact of k degD is complex and also involves the period. Thus, if t 1/2 = 4 h, all the drug that has been supplied at the beginning of the 24 h period, has been eliminated at the end of it and the average drug load is constant. However, if t 1/2 = 12 h, then after 24 h a considerable amount of drug will still be in the system and the average drug load will climb to a higher level.
In order to better compare our results for small and large molecules, we calculated D ave for doses giving 1, 2, 3 × 10 3 K d as initial concentration assuming a simple linear kinetics (cf. Appendix C). The resulting simulations are shown in Fig. 7 . We note that arriving at steady state takes some time in the case of the large molecule, whereas this is achieved rapidly in the case of the small molecule. However, at steady state, the velocity of inhibited μP 2 production is similar, for example ca 6.5 × 10 −9 μM/min for the large molecule versus ca 5.5 × 10 −9 μM/min for the small molecule case at the maximum D ave dose of 0.694 and 0.302 (approximately 63% and 75% inhibition for the large vs. small molecule respectively). We conclude from this that the large and small drug options may both efficiently control reaction velocity with doses that are viable from a drug discovery perspective.
Discussion
One advantage of the System-Pharmacological approach is that it incorporates known physiological compartmentalisation information, as well as the molecular transduction events. This has the benefit that questions of interest to drug discoverers can be explored. For instance: Fig. 4 . Growth of μP 2 over 100 h (=6000 min ≈ 4 days) in Scenarios 1, 2 and 3 with ligand-receptor parameters, initial data given in Appendix B, doses in Table 3 .1 and drug-related rates given by Table 3 .2. The red -dashed -curve is obtained for D 1 (0) = 0 and D 2 (0) = 0. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) The red -dashed -curve is the endogenous growth curve when no drug is given. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Is a small molecule a better option than a large molecule? In this case the model enabled appropriate separation of the options according to PK principles i.e., small-molecules are likely to be permeable across biological membranes and large molecules are not. Furthermore, the model construction allowed incorporation of responses that straddle compartments that can be graphically represented and account for the concentrations of reactant sub-domains in different compartments. Our model system is inspired by the case of NGF (Sasagawa et al., 2005) . In order to simplify the analysis of the model we assume that the signal transduction and response is proportional to the concentration of phosphorylated receptors. This assumption is inherent in previous modelling work and various data on this system has been published extensively (Ahmed et al., 2014) including in vitro data that are reproducibly consistent with model predictions (cf. . Thus, the models would appear to describe the observed data we know of and be the best available tools we have to interrogate these complex signal transduction systems. However, the paucity of in vivo human data, the potential for influence by as yet unknown interactions and the simplification inherent in the mathematical models preclude absolute confidence in predictions. Thus, any conclusions drawn should be made in this context. In this manuscript, we reduce the signal transduction model to its first two steps only. This has the advantage that analysis of the behaviour can be focused and simplified and understanding applied in the context of a more complete transduction model such as the Sasagawa model. Thus, a modular analysis of pathway sub-sections becomes possible that should enable further understanding of complex system properties.
Our results show that within the boundaries of the assumptions made, there is no particularly evident advantage to targeting the ligand versus the catalysis for the subsequent phosphorylation step (e.g. with a kinase inhibitor). Assuming typical PK and pharmacology parameters both large and small molecule options can inhibit the pathway to the same extent with doses and regimens that sit well within the typically used tractable region. Arguably, the use of an antibody like molecule has the advantages of limited risk of off target toxicity and less frequent dosing, but the disadvantage of higher cost and requiring iv or sc dosing. Conversely, the small molecule option carries the advantages of lower cost and potential for oral self-administration. One argument for targeting pathways downstream of the initiating stimulus is that it may have better specificity, under the assumption that the stimulus itself may have pleiotropic activity (Bracci-Laudiero and De Stefano, 2016) , whereas the down-stream step is more likely to have response specificity (Boison et al., 2011) . Given our analysis reveals that targeting the kinase is as good as the ligand, at least from an efficacy perspective, then the optimal choice would be the small molecule. However, the generality of this conclusion may be challenged in several ways. For example, this finding may be influenced by the particular parameter combination assumptions. This model will enable a systematic exploration of the generality of our conclusions, given a range of parameter space. Furthermore, the model is a reduction of a signal transduction pathway to its first two steps. By including further mechanistic details, such as for example feedback loops often observed in signalling pathways, such as negative feedback regulation of the ERK1/2 MAPK pathway (cf. Lake et al., 2016) , the influence of these on this conclusion can be explored in tandem with and related to our simplified two step model. Typical parameter values for the ligand-receptor-membrane system display a wide range of values which makes it possible to reduce the full system given by Eqs. (2.1)-(2.4) to a simpler system which yields accurate approximations, except for the start-up period. This reduction will be used in modelling the different inhibition scenarios.
We base our analysis on parameter values taken from Sasagawa et al. (2005) , listed in Table B1 . Note that 
For the volume of the interstitial fluid compartment V 1 and the cellular compartment V 2 we take V 1 = 12 L and V 2 = 10 −3 L.
The former is a well-known estimate and the latter is based on a neuron volume of 1 nL (cf. Groves and Rebec, 1988) and a target population of neurons (e.g. containing pain sensors) of 1 million. This results in the estimate given for V 2 (see also Campenot, 2009 ).
In the simulations the initial concentrations are taken to be the baseline values in the absence of phosphorylation, i.e. when k cat = 0. They are defined by Eqs. (2.8) and (2.9). For the parameter values in Table B1 , they are shown in Table B2 . 
